3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
128
Colonic Neoplasms
54
Rectal Neoplasms
49
Carcinoma, Hepatocellular
29
Stomach Neoplasms
23
Neoplasm Metastasis
20
Pancreatic Neoplasms
10
Cholangiocarcinoma
9
Neoplasms
8
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
7
Liver Neoplasms
6
Gastrointestinal Neoplasms
5
Biliary Tract Neoplasms
5
Recurrence
4
Ovarian Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Digestive System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Unresectable Metastatic Colorectal Cancer
2
Neurotoxicity Syndromes
2
Neoplastic Cells, Circulating
2
Intestinal Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Colorectal Cancer Metastatic
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Breast Neoplasms
2
Adenocarcinoma
2
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Everolimus
7
lutetium Lu 177 dotatate
4
lanreotide
4
Sunitinib
4
Temozolomide
3
Octreotide
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Capecitabine
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Quality of Life
2
FAPI-46
2
veliparib
1
tivozanib
1
tislelizumab
1
telotristat ethyl
1
surufatinib
1
romidepsin
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pasireotide
1
gallium Ga 68 dotatate
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Folfox protocol
×
Gastrointestinal
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled